The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])
J.et al (2016)
Ongoing post-marketing surveillance and real-world evidence will continue to inform our understanding of Mounjaro's safety profile, including any potential effects on mental health and emotional wellbeing
When you eat less food, it becomes easy to fall short on protein without realizing it
"If the half-life is 5 days, the medication is gone after 5 days" False
4d), among which six ferroptosis-inhibiting genes (Slc7a11, Slc40a1, Gclm, Fth1, Gclc, and Gss) were upregulated, one ferroptosis-promoting gene (Slc39a14) was downregulated, and one ferroptosis-promoting gene (Hmox1) was upregulated